Acute Chagas disease is caused by the protozoan Trypanosoma cruzi, transmitted primarily by triatomine ("kissing bug") vectors, and presents as a nonspecific febrile illness lasting 4–12 weeks that is asymptomatic or undetected in >98% of cases. [1-2] When recognized, it is a treatable infection with 80–100% cure rates using antiparasitic therapy in the acute phase. [1] The following is a comprehensive clinical summary organized for emergency medicine and primary care workflows.
The following table from the NEJM summarizes the diagnosis and management across all phases of Chagas disease:
1. History
- Travel/residence: Prolonged stay (>6 months) in Mexico, Central America, or South America — the single most important screening question [3-4]
- Exposure mechanism: Sleeping in mud/thatch-walled housing (triatomine habitat), consumption of uncooked fruit juices (açaí, sugarcane — oral transmission), blood transfusion, organ transplant, maternal history of Chagas (congenital) [2][5]
- Timing: Symptoms appear 1–2 weeks after vector-borne exposure, or up to 3–4 months after transfusion/transplant [2][6]
- Symptom characterization: Fever (often intermittent), malaise, headache, myalgia, anorexia, facial/limb edema, diarrhea [5][7]
- Pathognomonic signs: Unilateral painless periorbital edema (Romaña sign — conjunctival portal of entry, ~50% of symptomatic cases) or skin nodule at bite site (chagoma, ~25%) [2][7]
- Important negatives: Absence of rash (unlike dengue), no cyclic fevers (unlike malaria), no posterior cervical lymphadenopathy (unlike African trypanosomiasis)
2. Alarm Features
- Acute myocarditis: Chest pain, dyspnea, tachycardia out of proportion to fever, hypotension — occurs in <5% but carries significant mortality [2][5]
- Pericardial effusion: May accompany myocarditis [5]
- Meningoencephalitis: Altered mental status, seizures, focal neurologic deficits — ~1% of acute cases, higher mortality in infants and immunocompromised [1][7]
- Oral transmission outbreaks: Associated with more severe disease, higher rates of myocarditis, and higher case-fatality rates than vector-borne infection [1-2]
- Immunocompromised patients (HIV with CD4 <200, transplant recipients): At risk for fulminant reactivation with CNS chagomas mimicking toxoplasmosis, or cardiogenic shock [4][8]
3. Medications
- First-line: Benznidazole 5–8 mg/kg/day PO in 2 divided doses × 60 days (max 300 mg/day recommended by most experts) [4]
- Alternative: Nifurtimox 8–10 mg/kg/day PO in 3 divided doses × 60 days [4]
- Benznidazole preferred due to better tolerability and tissue penetration [2][5]
- Higher doses (up to 15 mg/kg) recommended for meningoencephalitis [5]
- Adverse effects:
- Benznidazole: Dermatitis/photosensitivity rash (~30%), peripheral neuropathy (~30%), GI intolerance, bone marrow suppression (rare) [5][9]
- Nifurtimox: Anorexia/weight loss, neuropsychiatric symptoms (irritability, insomnia), nausea/vomiting, peripheral neuropathy; discontinuation rates 14.5–75% [5]
- Contraindications: Pregnancy, breastfeeding, severe hepatic or renal insufficiency, advanced chagasic cardiomyopathy [3-4]
- FDA approvals: Benznidazole approved for children 2–12 years; nifurtimox approved for children birth to <18 years (≥2.5 kg). Adult use is off-label but standard practice [3-4]
- Mild drug reactions (rash, GI) can be managed with antihistamines or short-course corticosteroids; discontinue immediately for severe/exfoliative dermatitis or dermatitis with fever and lymphadenopathy [5][9]
4. Diet
- No specific dietary triggers for acute Chagas disease
- Oral transmission route: Contaminated fresh fruit juices (açaí, sugarcane, guava) and food contaminated with triatomine feces — counsel patients from endemic areas about this risk [1-2]
- Ensure adequate hydration and nutrition during febrile illness
- Both benznidazole and nifurtimox should be taken with food to reduce GI side effects [6]
5. Review of Systems
- Constitutional: Fever, malaise, fatigue, weight loss, night sweats
- Cardiac: Palpitations, chest pain, dyspnea, syncope, exercise intolerance
- Neurologic: Headache, confusion, seizures, focal deficits
- GI: Anorexia, nausea, diarrhea, abdominal pain
- Skin: Bite site nodule, facial/periorbital swelling, rash, limb edema
- Ophthalmologic: Unilateral eyelid swelling (Romaña sign)
- Lymphatic: Generalized lymphadenopathy
6. Collateral History and Family History
- Maternal Chagas status: Critical for neonates — congenital transmission occurs in 1–10% of pregnancies in seropositive mothers [3]
- Household contacts: Shared exposure to triatomine-infested housing; screen family members from endemic areas
- Blood/organ donation history: Both donor and recipient screening relevant [3-4]
- Immigration history: Country of origin, rural vs. urban dwelling, housing conditions
- HIV status: Coinfection dramatically increases risk of reactivation and severe disease [4][8]
7. Risk Factors
- Geographic: Residence in rural Latin America (21 endemic countries), particularly in adobe/thatch housing [5][10]
- Socioeconomic: Poverty, poor housing conditions, agricultural work
- Oral transmission: Consumption of contaminated beverages — increasingly recognized cause of outbreaks with more severe disease [1-2]
- Transfusion/transplant: Blood products or organs from endemic-area donors (universal screening now in place in endemic countries and US blood banks) [3][10]
- Congenital: Maternal T. cruzi infection
- Immunosuppression: HIV (especially CD4 <200), organ transplant recipients, chemotherapy — risk of reactivation of chronic infection [4][8]
- Age: Young children and infants at higher risk for severe acute disease [1][6]
8. Differential Diagnosis
- Infectious mononucleosis / EBV: Fever, lymphadenopathy, hepatosplenomegaly, atypical lymphocytes — very similar presentation; Chagas has been described as a "mononucleosis-like" syndrome [7]
- Malaria: Febrile illness in returning traveler; thick/thin smear differentiates; no periorbital edema
- Dengue / Zika / Chikungunya: Febrile illness from Latin America; rash and arthralgias more prominent
- Toxoplasmosis: Lymphadenopathy, fever; CNS lesions in immunocompromised — brain chagomas mimic toxoplasmosis on imaging but tend to be larger [4]
- Visceral leishmaniasis: Fever, hepatosplenomegaly, pancytopenia; different vector and geography
- African trypanosomiasis (T. brucei): Distinguished by geography (sub-Saharan Africa), tsetse fly vector, posterior cervical lymphadenopathy (Winterbottom sign), and smaller kinetoplast on smear [11-12]
- Acute viral myocarditis: If cardiac presentation predominates; travel history and parasitemia distinguish
- Typhoid fever, brucellosis, tuberculosis: Other causes of prolonged fever in returning travelers
- Periorbital cellulitis / allergic angioedema: If Romaña sign is the presenting feature
9. Past Medical History
- Prior residence in endemic areas (even decades ago — chronic infection may reactivate)
- Previous blood transfusions or organ transplants
- HIV/AIDS status and CD4 count
- Immunosuppressive therapy (transplant, autoimmune disease, chemotherapy)
- Prior cardiac history (baseline ECG abnormalities)
- Pregnancy status (treatment contraindicated; congenital transmission risk)
10. Physical Exam
- Vital signs: Fever (often low-grade), tachycardia out of proportion to fever (early cardiac involvement) [2]
- Eyes: Unilateral painless periorbital edema (Romaña sign) — pathognomonic [2][7]
- Skin: Chagoma (erythematous, indurated nodule at inoculation site); facial/limb edema; rash (uncommon) [7]
- Lymph nodes: Generalized lymphadenopathy [5]
- Abdomen: Hepatomegaly, splenomegaly [1][5]
- Cardiac: Tachycardia, irregular rhythm, muffled heart sounds (pericardial effusion), signs of heart failure (JVD, peripheral edema, pulmonary crackles) if myocarditis [2][5]
- Neurologic: Mental status changes, meningismus, focal deficits (if meningoencephalitis) [4]
11. Lab Studies
- Diagnostic (acute phase):
- Giemsa-stained thick and thin blood smears or buffy coat preparation — standard for acute diagnosis; look for trypomastigotes with large posterior kinetoplast and "C" shape [11]
- PCR for T. cruzi DNA — higher sensitivity, useful adjunct to microscopy [3][13]
- Fresh wet mount of anticoagulated blood may show motile organisms (not routinely performed in US labs) [11]
- Supportive labs:
- CBC: Atypical lymphocytosis, possible anemia, thrombocytopenia [1][7]
- CMP: Elevated AST/ALT (hepatic involvement), renal function (baseline before treatment) [5]
- Troponin, BNP/NT-proBNP: If myocarditis suspected
- ESR/CRP: Nonspecific elevation
- Serology: Not reliable in acute phase (antibodies may not yet be present); two different serologic tests (ELISA + IFA using different antigens) required for chronic phase diagnosis [3-4]
- Monitoring during treatment: CBC (bone marrow suppression with benznidazole), LFTs, renal function [3][9]
12. Imaging
- Chest X-ray: Cardiomegaly if myocarditis or pericardial effusion; baseline for all diagnosed patients [6]
- Echocardiography: Indicated if cardiac symptoms or ECG abnormalities; in acute Chagas, pericardial effusion is the most common finding (~42%), decreased LVEF (~37%), apical/anterior dyskinesis (~21%) [14]
- CT/MRI brain: If meningoencephalitis suspected — subcortical hypodense/enhancing white matter lesions (chagomas); in HIV coinfection, must differentiate from CNS toxoplasmosis (chagomas tend to be larger) [4]
- Imaging is unnecessary in mild, uncomplicated acute febrile illness without cardiac or neurologic symptoms
13. Special Tests
- Buffy coat concentration technique: Improves sensitivity of microscopy by concentrating trypomastigotes just above the buffy coat layer [4]
- Quantitative PCR (qPCR): Serial specimens useful for monitoring parasitemia, especially in immunocompromised patients and for detecting reactivation [4]
- Hemoculture: More sensitive than direct microscopy but takes 2–8 weeks — not useful for acute ED decision-making [4]
- CSF analysis (if meningoencephalitis): Mild lymphocytic pleocytosis, elevated protein, trypomastigotes visible in 85% of HIV-coinfected patients with CNS reactivation [4]
- CDC Parasitic Diseases Hotline: 404-718-4745 or parasites@cdc.gov — for consultation on diagnosis, management, and drug access [2][4]
14. ECG
- Obtain on all patients with suspected or confirmed acute Chagas disease [3][14]
- Mild acute disease: Sinus tachycardia, PR and QT prolongation, low-voltage QRS complexes, nonspecific repolarization (ST-T) abnormalities [2][14]
- Acute myocarditis: Diffuse ST changes, AV block (first-degree to complete), bundle branch blocks (RBBB most characteristic), atrial and ventricular premature complexes [2][14]
- Danger signs on ECG: Right bundle-branch block, atrial fibrillation, ventricular arrhythmias — signal worse prognosis and need for admission [2]
- ECG abnormalities documented in 41–66% of symptomatic acute cases [14]
15. Assessment
- Acute Chagas disease is overwhelmingly mild and self-limited in immunocompetent patients, resolving spontaneously in ~90% even without treatment. However, without treatment, patients remain chronically infected for life, and 20–40% will develop cardiomyopathy or megaviscera decades later. [5-6]
- Severe acute disease (<1–5%) includes myocarditis, pericardial effusion, and meningoencephalitis, with mortality of 0.2–0.5% overall and <5–10% among symptomatic cases. [5-6]
- Oral transmission outbreaks produce more severe disease with higher hospitalization and mortality rates. [1-2]
- Immunocompromised patients (HIV, transplant) may present with fulminant reactivation — CNS disease (85% of reactivation cases) carries 79% mortality. [8]
- The key clinical challenge is recognition: >98% of acute infections go undiagnosed because symptoms are nonspecific. [1][11]
16. Treatment Plan
Initial stabilization (ED):
- ABCs; IV access, cardiac monitoring if hemodynamically unstable or ECG abnormalities
- Treat fever and dehydration supportively
Antiparasitic therapy (initiate as soon as parasitological or serological confirmation obtained):
- Benznidazole 5–8 mg/kg/day PO divided BID × 60 days (max 300 mg/day) — first-line [4]
- Nifurtimox 8–10 mg/kg/day PO divided TID × 60 days — alternative [4]
- For meningoencephalitis: Benznidazole up to 15 mg/kg/day [5]
- Cure rate in acute phase: 76–100% [2][5]
Myocarditis management:
- Standard heart failure therapy as needed (diuretics, vasodilators)
- Continuous telemetry; treat arrhythmias per ACLS protocols
- Echocardiography for hemodynamic assessment [14]
Immunocompromised patients:
- Initiate/optimize ART in HIV-coinfected patients [4]
- Treat reactivation with same antiparasitic regimens; mortality remains high even with treatment [4]
17. Disposition
Admit if:
- ECG abnormalities (AV block, RBBB, ventricular arrhythmias, atrial fibrillation) [2]
- Clinical myocarditis or pericardial effusion
- Meningoencephalitis or altered mental status
- Hemodynamic instability
- Immunocompromised with suspected reactivation
- Neonates with symptomatic congenital infection
Discharge with close follow-up if:
- Mild febrile illness without cardiac or neurologic involvement
- Normal ECG and stable vital signs
- Able to tolerate oral medications
- Reliable follow-up with infectious disease specialist arranged
Consult:
- Infectious disease — all confirmed or suspected cases; CDC Parasitic Diseases Hotline (404-718-4745) for drug access and management guidance [2][4]
- Cardiology — if any cardiac involvement
- Neurology — if CNS symptoms
18. Follow Up / Return Precautions
- Follow-up timing: Within 1 week of discharge for medication tolerance check; then every 2 weeks during 60-day treatment course for CBC, LFTs, and adverse effect monitoring [3][9]
- Post-treatment: Serologic follow-up to document seroconversion (may take months to years in adults) [5]
- Annual ECG: Recommended for all patients with confirmed T. cruzi infection, even after successful acute treatment, to monitor for late cardiac manifestations [1][3]
- Return precautions — seek immediate care for:
- Chest pain, palpitations, syncope, or worsening dyspnea
- Severe headache, confusion, seizures, or focal weakness
- Severe rash, exfoliative dermatitis, or rash with fever/lymphadenopathy (drug reaction — stop medication)
- Numbness/tingling in extremities (peripheral neuropathy from treatment)
- Counseling: Cannot donate blood or organs; inform about congenital transmission risk for women of childbearing age; screen household members and children of seropositive mothers [3-4]
- Expected course: Acute symptoms typically resolve within 4–8 weeks even without treatment, but antiparasitic therapy is essential to prevent chronic sequelae [1][6]
References
1. Chagas’ Disease. — Bern C. The New England Journal of Medicine. 2015.
2. Chagas’ Disease. — Bern C. The New England Journal of Medicine. 2015.
3. Chagas’ Disease. — Bern C. The New England Journal of Medicine. 2015.
4. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. — Nunes MCP, Beaton A, Acquatella H, et al. Circulation. 2018.
5. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. — Nunes MCP, Beaton A, Acquatella H, et al. Circulation. 2018.
6. Neglected Parasitic Infections: What Family Physicians Need to Know—A CDC Update. — Cantey PT, Montgomery SP, Straily A. American Family Physician. 2021.
7. Neglected Parasitic Infections: What Family Physicians Need to Know—A CDC Update. — Cantey PT, Montgomery SP, Straily A. American Family Physician. 2021.
8. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
9. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
10. Chagas Disease. — Pérez-Molina JA, Molina I. Lancet. 2018.
11. Chagas Disease. — Pérez-Molina JA, Molina I. Lancet. 2018.
12. Chagas Disease. — Rassi A, Rassi A, Marin-Neto JA. Lancet. 2010.
13. Chagas Disease. — Rassi A, Rassi A, Marin-Neto JA. Lancet. 2010.
14. Chronic Chagas Heart Disease Management: From Etiology to Cardiomyopathy Treatment. — Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Journal of the American College of Cardiology. 2017.
15. Chronic Chagas Heart Disease Management: From Etiology to Cardiomyopathy Treatment. — Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Journal of the American College of Cardiology. 2017.
16. The Epidemiology and Clinical Features of HIV and Trypanosoma Cruzi (Chagas Disease) Co-Infection: A Systematic Review and Individual Patient Data Analysis. — Elkheir N, Carter J, Dominic C, et al. PLoS Neglected Tropical Diseases. 2026.
17. The Epidemiology and Clinical Features of HIV and Trypanosoma Cruzi (Chagas Disease) Co-Infection: A Systematic Review and Individual Patient Data Analysis. — Elkheir N, Carter J, Dominic C, et al. PLoS Neglected Tropical Diseases. 2026.
18. Evaluation and Treatment of Chagas Disease in the United States: A Systematic Review. — Bern C, Montgomery SP, Herwaldt BL, et al. The Journal of the American Medical Association. 2007.
19. Evaluation and Treatment of Chagas Disease in the United States: A Systematic Review. — Bern C, Montgomery SP, Herwaldt BL, et al. The Journal of the American Medical Association. 2007.
20. Global, Regional, and National Burden of Chagas Disease, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023. — GBD 2023 Chagas Disease and RAISE Study Collaborators. The Lancet. Infectious Diseases. 2026.
21. Global, Regional, and National Burden of Chagas Disease, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023. — GBD 2023 Chagas Disease and RAISE Study Collaborators. The Lancet. Infectious Diseases. 2026.
22. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
23. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
24. Clinical Features, Diagnosis, and Treatment of Human African Trypanosomiasis (Sleeping Sickness). — Kennedy PG. The Lancet. Neurology. 2013.
25. Clinical Features, Diagnosis, and Treatment of Human African Trypanosomiasis (Sleeping Sickness). — Kennedy PG. The Lancet. Neurology. 2013.
26. Nutritional Heart Disease And Cardiomyopathies: JACC Focus Seminar 4/4. — Sliwa K, Viljoen CA, Hasan B, Ntusi NAB. Journal of the American College of Cardiology. 2022.
27. Nutritional Heart Disease And Cardiomyopathies: JACC Focus Seminar 4/4. — Sliwa K, Viljoen CA, Hasan B, Ntusi NAB. Journal of the American College of Cardiology. 2022.
28. Recommendations for Multimodality Cardiac Imaging in Patients With Chagas Disease: A Report From the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). — Acquatella H, Asch FM, Barbosa MM, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2018.
29. Recommendations for Multimodality Cardiac Imaging in Patients With Chagas Disease: A Report From the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). — Acquatella H, Asch FM, Barbosa MM, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2018.